Quantitative Investment Management LLC purchased a new stake in AstraZeneca plc (NYSE:AZN) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 360,600 shares of the company’s stock, valued at approximately $12,512,000.
Other institutional investors have also bought and sold shares of the company. Pinnacle Wealth Planning Services Inc. purchased a new stake in shares of AstraZeneca in the fourth quarter valued at approximately $101,000. Valeo Financial Advisors LLC purchased a new stake in shares of AstraZeneca in the third quarter valued at approximately $133,000. Delpha Capital Management LLC purchased a new stake in shares of AstraZeneca in the fourth quarter valued at approximately $152,000. Calton & Associates Inc. purchased a new stake in shares of AstraZeneca in the fourth quarter valued at approximately $181,000. Finally, Wealthcare Advisory Partners LLC purchased a new stake in shares of AstraZeneca in the third quarter valued at approximately $184,000. Hedge funds and other institutional investors own 15.13% of the company’s stock.
Shares of AstraZeneca plc (NYSE:AZN) opened at $33.79 on Friday. The company has a current ratio of 0.80, a quick ratio of 0.62 and a debt-to-equity ratio of 0.93. The company has a market capitalization of $85,561.23, a price-to-earnings ratio of 7.89, a price-to-earnings-growth ratio of 2.02 and a beta of 0.71. AstraZeneca plc has a 12-month low of $28.43 and a 12-month high of $36.70.
The company also recently announced a semiannual dividend, which will be paid on Monday, March 19th. Shareholders of record on Friday, February 16th will be given a dividend of $0.95 per share. The ex-dividend date of this dividend is Thursday, February 15th. This represents a yield of 5.62%. AstraZeneca’s payout ratio is 57.81%.
AZN has been the topic of a number of analyst reports. Zacks Investment Research upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research note on Monday, January 22nd. BMO Capital Markets set a $38.00 price target on AstraZeneca and gave the company a “buy” rating in a research note on Wednesday, January 10th. Sanford C. Bernstein lifted their price target on AstraZeneca from $40.00 to $42.00 and gave the company an “outperform” rating in a research note on Monday, February 5th. Leerink Swann restated a “market perform” rating and issued a $36.00 price target (up from $33.00) on shares of AstraZeneca in a research note on Thursday, January 18th. Finally, JPMorgan Chase & Co. upgraded AstraZeneca from a “neutral” rating to an “overweight” rating in a research note on Friday, December 29th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $36.26.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.